

AGI-026

Chemical Properties

CAS No. : 1446501-77-4


Formula: C₁₈H₁₅F₆N₇

Molecular Weight: 443.35

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	AGI-026 (AGI-12026) is a novel and potent dual inhibitor of the mutant isocitrate dehydrogenase IDH1/2 with the advantages of oral administration and penetration of the blood-brain barrier, with a drug concentration to plasma concentration ratio (brain/plasma ratio) of 1.5 in brain tissue, and the ability to reduce the accumulation of the carcinogenic metabolite d-2-hydroxyglutarate (2-HG), which is used in the study of IDH gliomas.
Targets(IC50)	Isocitrate Dehydrogenase (IDH)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2556 mL	11.2778 mL	22.5555 mL
5 mM	0.4511 mL	2.2556 mL	4.5111 mL
10 mM	0.2256 mL	1.1278 mL	2.2556 mL
50 mM	0.0451 mL	0.2256 mL	0.4511 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Konteatis Z, et al. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Med Chem Lett. 2020;11(2):101-107.

Wang F, et al. A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model. J Inherit Metab Dis. 2016 Nov;39(6):807-820.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481